Opsumit Reduces PAH Severity by Halting Associated Metabolic Changes, Study Shows
Pulmonary arterial hypertension (PAH) severity is associated with alterations in the heart’s metabolism, but a recent study showed that Opsumit (macitentan) can reduce these metabolic changes, lessening PAH severity and easing strain on the heart’s right ventricle. The study, “Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function…
